Price:
Rs. 60,000.00
Sample Type: Maternal Blood
Fasting Not Required
Booking Procedure:
- Technician from Metropolis will be assigned for a home sample collection after booking confirmation.
- Sample will be collected by our technician at your address at given slot.
- You can make the payment to the technician at the time of collection
- Your sample will then be transported to the nearest collection center and will be centrifuged before sending to the lab for processing.
- Soft copy reports will be sent to your email address within 24 to 48 hours or as per defined TAT for Tests.
Frequently Asked Questions (FAQ's):
What does the NextGen LiquiCore 118 Gene Panel (MSI) at Metropolis Healthcare include?
It analyzes 118 cancer-associated genes and assesses MSI status to guide targeted therapy and immunotherapy decisions.
How does Metropolis Healthcare perform this liquid biopsy test?
Metropolis Healthcare uses high-depth NGS to detect tumor-derived DNA mutations from a blood sample with excellent precision.
Who should consider this LiquiCore 118 Gene Panel at Metropolis Healthcare?
Individuals with solid tumors, those unable to undergo tissue biopsy, or patients needing molecular profiling for advanced treatments should take this test.
Is fasting required for the LiquiCore liquid biopsy at Metropolis Healthcare?
No, fasting is not required; a simple blood draw is sufficient.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to in-depth sequencing and complex genomic analysis.
Can this test at Metropolis Healthcare guide cancer treatment?
Yes, it helps identify actionable mutations and MSI status, which are crucial for selecting targeted therapies and immunotherapies.
How accurate is this liquid biopsy panel at Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy with ultra-deep sequencing, validated workflows, and expert molecular interpretation.
Can this test help monitor cancer progression at Metropolis Healthcare?
Yes, it can be used for ongoing monitoring of tumor mutations and treatment response using a non-invasive blood sample.